Results 61 to 70 of about 35,270 (248)
Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia [PDF]
Journal of Microbiology and Infectious Diseases, 2016 Objective: Pediatric cancer patients with prolonged febrile neutropenia have increased risk for severe, recurrent or new bacterial and fungal infection.
Muhammad Matloob Alam
doaj +1 more source
British Journal of Haematology, EarlyView.Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas +35 more
wiley +1 more source
Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim
, 2019 Aim: Neutropenia is a common side effect of myelosuppressive chemotherapy. Administration of granulocyte colony-stimulating factor is being used for neutropenia prophylaxis, but there are patients who develop neutropenia or febrile neutropenia despite ...
곽혜선
core +1 more source
British Journal of Haematology, EarlyView.Summary To assess the cost‐effectiveness of blinatumomab plus chemotherapy for paediatric patients from Hong Kong public healthcare provider's perspective, a 10‐year Markov model was designed to simulate outcomes in paediatric patients with newly diagnosed standard‐risk B‐cell ALL at: (1) average risk and (2) high risk of relapse.
Mingjun Rui +7 more
wiley +1 more source
Acta Médica Portuguesa, 2008 The administration of cytotoxic chemotherapy may be complicated by the emergence of neutropenia and febrile neutropenia, frequently determining hospital admission and intravenous treatment with broad spectrum antibiotics.
João Forjaz de Lacerda +5 more
doaj +1 more source
Cancer Science, EarlyView.The dose escalation part of the first‐in‐human study of E7130 in patients with advanced solid tumors determined the Recommended Phase 2 Dose of E7130 (480 μg/m2 Q3W). The dose expansion part (presented here) examined safety/preliminary efficacy in patients with squamous cell carcinoma of the head and neck and urothelial carcinoma.
Nobuaki Matsubara +15 more
wiley +1 more source
Cancer Science, EarlyView.The flow of this trial and the treatment schedule of adjuvant chemotherapy with nedaplatin plus docetaxel for completely resected non‐small cell lung cancer (NSCLC) (A). The primary endpoint of this study was tolerability, assessed by the completion rate of the planned four chemotherapy cycles. As a result, it was 74.3%, exceeding that reported for the
Koji Teramoto +9 more
wiley +1 more source
Management of febrile neutropenia [PDF]
, 2007 Neutropenia is a severe and very frequent complication of anticancer chemotherapy. Febrile neutropenia is a serious consequence of neutropenia caused by cancer chemotherapy, often leads to hospitalization, need of parenteral antibiotics and lethal end ...
Vachek, Jan
core
Occurrence of febrile neutropenia and neutropenia grade on day 8.
, 2019 Occurrence of febrile neutropenia and neutropenia grade on day 8.
Yoshihiko Furuya (6612659)
core +1 more source
Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”?
American Journal of Hematology, EarlyView.
Sudhir Tauro, Ayalew Tefferi
wiley +1 more source